MyFinsight
Home
Blog
About
Maturities of
available-for-sale marketable...
$37,200K
(-56.22%↓ Y/Y)
Proceeds from issuance of
common stock under the...
$74K
Net cash provided by
investing activities
$33,168K
(-24.27%↓ Y/Y)
Net cash provided by
(used in) financing...
$67K
(127.57%↑ Y/Y)
Canceled cashflow
$4,069K
Canceled cashflow
$7K
Net decrease in
cash, cash...
$13,722K
(2660.07%↑ Y/Y)
Canceled cashflow
$19,513K
Purchases of
available-for-sale marketable...
$3,907K
(-90.42%↓ Y/Y)
Purchases of property and
equipment
$125K
(-69.88%↓ Y/Y)
Proceeds from sale of
property and equipment
-$37K
(-200.00%↓ Y/Y)
Accrued expenses and
other current...
$2,915K
(217.73%↑ Y/Y)
Stock-based compensation
expense
$2,268K
(-63.12%↓ Y/Y)
Non-cash lease expense
$1,355K
(-49.14%↓ Y/Y)
Depreciation
$1,265K
(-53.03%↓ Y/Y)
something is missing
$1,111K
Impairment of right of use
assets
$634K
Prepaid expenses and
other assets
-$553K
(79.42%↑ Y/Y)
Accounts payable
$319K
(-86.03%↓ Y/Y)
Deferred revenue
$257K
Loss on fixed assets
write-off
-$181K
(-200.00%↓ Y/Y)
Other non-current
liabilities
$64K
(-55.24%↓ Y/Y)
Payment of deferred
financing costs
$7K
(-98.01%↓ Y/Y)
Net cash used in
operating activities
-$19,513K
(55.75%↑ Y/Y)
Canceled cashflow
$10,922K
Net loss
-$27,482K
(38.86%↑ Y/Y)
Operating lease
liabilities
-$1,466K
(47.98%↑ Y/Y)
Change in fair value of
long-term investments
-$1,292K
(-200.00%↓ Y/Y)
Accretion of discounts on
available-for-sale marketable...
$195K
(-89.32%↓ Y/Y)
Back
Back
Cash Flow
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX)
source: myfinsight.com